文森特:一项随机对照试验评估了新诊断的NPM1突变AML患者的venetoclax加azacitidine与密集化疗的对比
Lydia Kretschmer1, Leo Ruhnke2, Christoph Schliemann3
1Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany. lydia.kretschmer@ukdd.de.
Annals of hematology
|July 8, 2025
概括
该VINCENT试验将venetoclax (VEN) 与azacitidine (AZA) 与年轻急性髓性白血病 (AML) 患者的标准化疗进行比较. 这项研究将确定VEN/AZA是否提供与改善生活质量的可比疗效.
科学领域:
- 血液学 血液学 血液学
- 临床瘤学临床瘤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 适合患者的NPM1-突变,FLT3-野生型急性髓性白血病 (AML) 的标准密集化疗法产生高缓解率,但导致显著的毒性和影响生活质量 (QoL).
- 威尼托克拉克斯 (VEN) 与阿扎西提丁 (AZA) 结合在老年,不适合的AML患者中表现有前途,具有高疗效,毒性降低.
- 缺乏前性随机数据,直接将VEN/AZA与年轻,适合的AML患者的标准护理 (SOC) 进行比较.
研究的目的:
- 为了评估venetoclax (VEN) 加上azacitidine (AZA) 与标准护理 (SOC) 相比的非劣势,在年轻的,适合的成年人中,新诊断的NPM1-突变,FLT3-野生型急性髓性白血病 (AML).
- 评估疗效,安全性,耐受性和以患者为中心的结果,包括与健康相关的质量和医疗资源利用.
主要方法:
- 文森特试验是一个随机对照的,多中心的,第二阶段的非劣势性研究 (NCT05904106).
- 146名符合条件的成年患者 (18-70岁) 患有新诊断的,NPM1突变的,FLT3野生型AML,在医学上适合进行密集化疗 (ECOG ≤ 2),被随机分配1:1接受VEN/AZA或SOC.
- 主要终点是经过修改的无事件生存;次要终点包括缓解率 (CR/CRi/CRh/CRMRD-),MRD动力学,OS,安全性,QoL和医疗资源使用.
主要成果:
- 结果正在等待,因为试验正在进行中.
- 该研究旨在提供第一个全面的前性数据,将VEN/AZA与SOC在这个特定患者群体中进行比较.
结论:
- 该VINCENT试验准备确定VEN/AZA是否可以作为年轻,适合AML患者的SOC的有效替代品,可能改善结果和QOL.
- 这些发现将为NPM1突变型,FLT3野生型AML的治疗指南和个性化治疗策略提供信息.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
456
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
456
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
265
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
265
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K


